Last: | $1.41 |
---|---|
Change Percent: | 0.71% |
Open: | $1.39 |
Close: | $1.41 |
High: | $1.4899 |
Low: | $1.39 |
Volume: | 567,132 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.41 | $1.39 | $1.41 | $1.4899 | $1.39 | 567,132 | 05-31-2024 |
$1.4 | $1.34 | $1.4 | $1.44 | $1.34 | 477,270 | 05-30-2024 |
$1.35 | $1.37 | $1.35 | $1.37 | $1.32 | 459,162 | 05-29-2024 |
$1.38 | $1.39 | $1.38 | $1.4101 | $1.3201 | 532,057 | 05-28-2024 |
$1.4 | $1.38 | $1.4 | $1.43 | $1.35 | 438,889 | 05-27-2024 |
$1.4 | $1.38 | $1.4 | $1.43 | $1.35 | 438,889 | 05-24-2024 |
$1.35 | $1.47 | $1.35 | $1.47 | $1.3 | 978,212 | 05-23-2024 |
$1.43 | $1.45 | $1.43 | $1.45 | $1.42 | 333,120 | 05-22-2024 |
$1.42 | $1.48 | $1.42 | $1.5 | $1.4 | 804,501 | 05-21-2024 |
$1.48 | $1.44 | $1.48 | $1.48 | $1.4 | 754,314 | 05-20-2024 |
$1.46 | $1.48 | $1.46 | $1.52 | $1.44 | 1,138,481 | 05-17-2024 |
$1.47 | $1.42 | $1.47 | $1.54 | $1.42 | 1,289,376 | 05-16-2024 |
$1.47 | $1.35 | $1.47 | $1.48 | $1.34 | 1,452,340 | 05-15-2024 |
$1.37 | $1.38 | $1.37 | $1.39 | $1.32 | 859,090 | 05-14-2024 |
$1.37 | $1.37 | $1.37 | $1.4197 | $1.33 | 679,379 | 05-13-2024 |
$1.355 | $1.33 | $1.355 | $1.42 | $1.2905 | 1,406,261 | 05-10-2024 |
$1.29 | $1.285 | $1.29 | $1.325 | $1.26 | 471,359 | 05-09-2024 |
$1.28 | $1.29 | $1.28 | $1.32 | $1.27 | 297,237 | 05-08-2024 |
$1.32 | $1.28 | $1.32 | $1.34 | $1.27 | 547,937 | 05-07-2024 |
$1.29 | $1.33 | $1.29 | $1.3385 | $1.25 | 706,203 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in ...
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - ...
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, Al...